Grifols (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global leader in the production of plasma-derived medicines, and Mondragon, a worldwide leader in work cooperation and one of Spainâs most relevant business groups, today announced an agreement to jointly develop healthcare sector-related automation, robotics and instrumentation as well as other technologies and infrastructure.
A Joint Action Committee comprised of members from both companies will identify and prioritize initial projects over the next few months.
âGrifols is exceptionally pleased to collaborate with a highly renown technology and industrial leader such as the Mondragon group. The agreement represents an opportunity to jointly develop innovative technology solutions for the medical and pharmaceutical sectors, particularly projects related to instrumentation and robotics, which are constantly changing,â said Victor Grifols Deu and Raimon Grifols, co-CEOs of Grifols.
âFor Mondragon itâs enormously satisfying to sign this collaboration agreement with Grifols after many years of a positive relationship. The framework agreement is designed to drive innovation and new businesses in strategic areas such as health,â said IÃ±igo Ucin, president of Mondragon. Read more